ID   UT-SCC-54A
AC   CVCL_7863
SY   University of Turku-Squamous Cell Carcinoma-54A
DR   cancercelllines; CVCL_7863
DR   GEO; GSM2883378
DR   GEO; GSM2888841
DR   Wikidata; Q54992153
RX   DOI=10.1158/1538-7445.AM2020-507;
RX   PubMed=15287027;
RX   PubMed=17312569;
RX   PubMed=29970484;
RX   PubMed=30135316;
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu285Lys (c.853G>A); ClinVar=VCV000420133; Zygosity=Unspecified (PubMed=15287027).
CC   Omics: Array-based CGH.
CC   Omics: Deep exome analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Caution: UT-SCC-54A, UT-SCC-54B and UT-SCC-54C are supposed to originate from the same patient but the STR profile of UT-SCC-54C is totally different from that of the two other cell lines.
CC   Derived from site: In situ; Oral cavity, buccal mucosa; UBERON=UBERON_0006956.
ST   Source(s): PubMed=30135316
ST   Amelogenin: X
ST   CSF1PO: 10
ST   D13S317: 12
ST   D16S539: 11,12
ST   D18S51: 14,16
ST   D19S433: 14
ST   D21S11: 31,32.2
ST   D2S1338: 20,24
ST   D3S1358: 17
ST   D5S818: 11
ST   D7S820: 12
ST   D8S1179: 10,14
ST   FGA: 26
ST   TH01: 9.3
ST   TPOX: 8,9
ST   vWA: 14,18
DI   NCIt; C4040; Buccal mucosa squamous cell carcinoma
DI   ORDO; Orphanet_502363; Squamous cell carcinoma of the oral cavity
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_7864 ! UT-SCC-54B
OI   CVCL_A7DW ! UT-SCC-54C
SX   Female
AG   58Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 14
//
RX   DOI=10.1158/1538-7445.AM2020-507;
RA   Kondratyev M.K., Pesic A., Dvorkin-Sheva A., Ketela T., Moffat J.,
RA   Koritzinsky M., Wouters B.G.;
RT   "Repurposing of FDA approved drugs for treatment of metastatic HNSCC.";
RL   Cancer Res. 80 Suppl. 16:507-507(2020).
//
RX   PubMed=15287027; DOI=10.1002/gcc.20066;
RA   Takebayashi S., Hickson A., Ogawa T., Jung K.-Y., Mineta H., Ueda Y.,
RA   Grenman R., Fisher S.G., Carey T.E.;
RT   "Loss of chromosome arm 18q with tumor progression in head and neck
RT   squamous cancer.";
RL   Genes Chromosomes Cancer 41:145-154(2004).
//
RX   PubMed=17312569; DOI=10.1002/hed.20478;
RA   Lin C.J., Grandis J.R., Carey T.E., Gollin S.M., Whiteside T.L.,
RA   Koch W.M., Ferris R.L., Lai S.Y.;
RT   "Head and neck squamous cell carcinoma cell lines: established models
RT   and rationale for selection.";
RL   Head Neck 29:163-188(2007).
//
RX   PubMed=29970484; DOI=10.1158/1535-7163.MCT-17-0733;
RA   Lepikhova T., Karhemo P.-R., Louhimo R., Yadav B., Murumagi A.,
RA   Kulesskiy E., Kivento M., Sihto H., Grenman R., Syrjanen S.M.,
RA   Kallioniemi O.-P., Aittokallio T., Wennerberg K., Joensuu H., Monni O.;
RT   "Drug-sensitivity screening and genomic characterization of 45
RT   HPV-negative head and neck carcinoma cell lines for novel biomarkers
RT   of drug efficacy.";
RL   Mol. Cancer Ther. 17:2060-2071(2018).
//
RX   PubMed=30135316; DOI=10.1172/jci.insight.122204; PMCID=PMC6141174;
RA   Jamieson S.M.F., Tsai P., Kondratyev M.K., Budhani P., Liu A.,
RA   Senzer N.N., Chiorean E.G., Jalal S.I., Nemunaitis J.J., Kee D.,
RA   Shome A., Wong W.W., Li D., Poonawala-Lohani N., Kakadia P.M.,
RA   Knowlton N.S., Lynch C.R.H., Hong C.R., Lee T.W., Grenman R.,
RA   Caporiccio L., McKee T.D., Zaidi M., Butt S., Macann A.M.J.,
RA   McIvor N.P., Chaplin J.M., Hicks K.O., Bohlander S.K., Wouters B.G.,
RA   Hart C.P., Print C.G., Wilson W.R., Curran M.A., Hunter F.W.;
RT   "Evofosfamide for the treatment of human papillomavirus-negative head
RT   and neck squamous cell carcinoma.";
RL   JCI Insight 3:e122204.1-e122204.19(2018).
//